ENA 2024: Latest News
Scientists create cancer patients’ ‘digital twins’ to predict how well treatments may work
Friday 25 October 2024, Barcelona, Spain: Researchers have shown that they can accurately re-create clinical trials of new treatments using ‘digital twins’ of real cancer patients. The technology, called FarrSight®-Twin, which is based on algorithms [...]
Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300
Friday 25 October 2024, Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, [...]
Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors
Friday 25 October 2024, Barcelona, Spain: Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs. The yet-to-be-published findings are presented on Friday [...]
New ‘mini-protein’ carries radiation dose directly to tumours without harming healthy tissues
Friday 25 October 2024, Barcelona, Spain: Researchers have shown for the first time that it is possible for a specially-designed ‘mini-protein’ to deliver a radiation dose directly to tumour cells expressing a protein on [...]
Treatments used for HER2-positive breast cancers could help patients with rare gastrointestinal cancer
Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, [...]
New drug, WNTinib, delays tumour growth and improves survival in mouse models of children’s liver cancer
Wednesday 23 October 2024, Barcelona, Spain: A new drug called WNTinib can delay the growth of tumours and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children. This effect was [...]